Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study
Conditions:   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC v8;   Anatomic Stage IIIB Breast Cancer AJCC v8;   Anatomic Stage IIIC Breast Cancer AJCC v8;   Anatomic Stage IV Breast Cancer AJCC v8;   Clinical Stage III Cutaneous Melanoma AJCC v8;   Clinical Stage III Gastric Cancer AJCC v8;   Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage III Merkel Cell Carcinoma AJCC v8;   Clinical Stage IV Cutaneous Melanoma AJCC v8;   Clinical Stage IV Gastric Cancer AJCC v8;   Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IV Merkel Cell Carcinoma AJCC v8;   Clinical Stage IVA Gastric Cancer AJCC v8;   Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IVB Gastric Cancer AJCC v8;   Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Locally Advanced Cervical Carcinoma;   Locally Advanced Endometrial Carcinoma;   Locally Advanced Gastric Adenocarcinoma;   Locally Advanced Gastroesophageal Junction Adenocarcinoma;   Locally Advanced Head and Neck Squamous Cell Carcinoma;   Locally Advanced Hepatocellular Carcinoma;   Locally Advanced Lung Non-Small Cell Carcinoma;   Locally Advanced Malignant Solid Neoplasm;   Locally Advanced Melanoma;   Locally Advanced Merkel Cell Carcinoma;   Locally Advanced Renal Cell Carcinoma;   Locally Advanced Skin Squamous Cell Carcinoma;   Locally Advanced Triple-Negative Breast Carcinoma;   Locally Advanced Unresectable Breast Carcinoma;   Locally Advanced Unresectable Cervical Carcinoma;   Locally Advanced Unresectable Gastric Adenocarcinoma;   Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma;   Locally Advanced Unresectable Renal Cell Carcinoma;   Locally Advanced Urothelial Carcinoma;   Metastatic Cervical Carcinoma;   Metastatic Endometrial Carcinoma;   Metastatic Gastric Adenocarcinoma;   Metastatic Gastroesophageal Junction Adenocarcinoma;   Metastatic Head and Neck Squamous Cell Carcinoma;   Metastatic Hepatocellular Carcinoma;   Metastatic Lung Non-Small Cell Carcinoma;   Metastatic Malignant Solid Neoplasm;   Metastatic Melanoma;   Metastatic Merkel Cell Carcinoma;   Metastatic Renal Cell Carcinoma;   Metastatic Skin Squamous Cell Carcinoma;   Metastatic Triple-Negative Breast Carcinoma;   Metastatic Urothelial Carcinoma;   Pathologic Stage III Cutaneous Melanoma AJCC v8;   Pathologic Stage III Gastric Cancer AJCC v8;   Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage III Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIA Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIA Gastric Cancer AJCC v8;   Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IIIB Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIB Gastric Cancer AJCC v8;   Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IIIC Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIC Gastric Cancer AJCC v8;   Pathologic Stage IIID Cutaneous Melanoma AJCC v8;   Pathologic Stage IV Cutaneous Melanoma AJCC v8;   Pathologic Stage IV Gastric Cancer AJCC v8;   Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IV Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8;   Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8;   Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Prognostic Stage III Breast Cancer AJCC v8;   Prognostic Stage IIIA Breast Cancer AJCC v8;   Prognostic Stage IIIB Breast Cancer AJCC v8;   Prognostic Stage IIIC Breast Cancer AJCC v8;   Prognostic Stage IV Breast Cancer AJCC v8;   Skin Squamous Cell Carcinoma;   Stage III Cervical Cancer AJCC v8;   Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8;   Stage III Hepatocellular Carcinoma AJCC v8;   Stage III Lung Cancer AJCC v8;   Stage III Renal Cell Cancer AJCC v8;   Stage III Uterine Corpus Cancer AJCC v8;   Stage IIIA Cervical Cancer AJCC v8;   Stage IIIA Hepatocellular Carcinoma AJCC v8;   Stage IIIA Lung Cancer AJCC v8;   Stage IIIA Uterine Corpus Cancer AJCC v8;   Stage IIIB Cervical Cancer AJCC v8;   Stage IIIB Hepatocellular Carcinoma AJCC v8;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIB Uterine Corpus Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8;   Stage IIIC Uterine Corpus Cancer AJCC v8;   Stage IIIC1 Uterine Corpus Cancer AJCC v8;   Stage IIIC2 Uterine Corpus Cancer AJCC v8;   Stage IV Cervical Cancer AJCC v8;   Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8;   Stage IV Hepatocellular Carcinoma AJCC v8;   Stage IV Lung Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Stage IV Uterine Corpus Cancer AJCC v8;   Stage IVA Cervical Cancer AJCC v8;   Stage IVA Hepatocellular Carcinoma AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVA Uterine Corpus Cancer AJCC v8;   Stage IVB Cervical Cancer AJCC v8;   Stage IVB Hepatocellular Carcinoma AJCC v8;   Stage IVB Lung Cancer AJCC v8;   Stage IVB Uterine Corpus Cancer AJCC v8;   Triple-Negative Breast Carcinoma;   Unresectable Cervical Carcinoma;   Unresectable Endometrial Carcinoma;   Unresectable Gastric Adenocarcinoma;   Unresectable Gastroesophageal Junction Adenocarcinoma;   Unresectable Head and Neck Squamous Cell Carcinoma;   Unresectable Hepatocellular Carcinoma;   Unresectable Lung Non-Small Cell Carcinoma;   Unresectable Malignant Solid Neoplasm;   Unresectable Melanoma;   Unresectable Merkel Cell Carcinoma;   Unresectable Renal Cell Carcinoma;   Unresectable Skin Squamous Cell Carcinoma;   Unresectable Triple-Negative Breast Carcinoma;   Unresectable Urothelial Carcinoma
Interventions:   Drug: Cyclophosphamide;   Biological: Neoantigen Peptide Vaccine;   Biological: Pembrolizumab;   Biological: Sargramostim
Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

April 12, 2022Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Comments